person · Reporting owner
Van der Ploeg Leonardus H.T.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Scientific Officer | May 30, 2019 | June 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,339 |
Ending reported balance
After 2019-05-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-05-30 · Exercise / conversion · Acquired 5,000 · Balance 47,339 Row 2 · 2019-05-30 · Sale · Disposed 5,000 · Balance 42,339 F1: This transaction was executed in multiple trades at prices ranging from $25.11 to $25.64, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2019-05-31 · Exercise / conversion · Acquired 5,000 · Balance 47,339 Row 4 · 2019-05-31 · Sale · Disposed 5,000 · Balance 42,339 F2: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.33, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2025-11-16 | Direct | 13,611 |
Reported balance
After 2019-05-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-05-30 · Exercise / conversion · Acquired 5,000 · Balance 13,611 F3: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2025-11-16 | Direct | 8,611 |
Reported balance
After 2019-05-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-05-31 · Exercise / conversion · Acquired 5,000 · Balance 8,611 F3: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $25.11 to $25.64, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.33, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2019 Filed Jun 3, 2019 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · derivative · entry 6 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,611 Underlying: Common Stock · 5,000 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,000 | $25.10 | $125,500.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · nonDerivative · entry 4 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.33, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,000 | $4.59 | $22,950.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · nonDerivative · entry 3 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · derivative · entry 5 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,611 Underlying: Common Stock · 5,000 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,000 | $25.31 | $126,550.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · nonDerivative · entry 2 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F1 · price: This transaction was executed in multiple trades at prices ranging from $25.11 to $25.64, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,000 | $4.59 | $22,950.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · nonDerivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed May 30, 2019 16:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · derivative · entry 8 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,611 Underlying: Common Stock · 5,000 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 29, 2019 Filed May 30, 2019 16:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,000 | $25.51 | $127,550.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 5 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F2 · price: This transaction was executed in multiple trades at prices ranging from $25.18 to $26.02, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 30, 2019 16:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,000 | $4.59 | $22,950.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 4 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 140 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · derivative · entry 7 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,290 Underlying: Common Stock · 140 shares Expires 2027-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,860 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · derivative · entry 6 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,611 Underlying: Common Stock · 9,860 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 10,000 | $25.38 | $253,800.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 3 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F1 · price: This transaction was executed in multiple trades at prices ranging from $25.01 to $26.10, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 140 | $6.14 | $859.60 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 2 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 9,860 | $4.59 | $45,257.40 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 16:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009040 · a4.xml · derivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 200 | $30.00 | $6,000.00 |
DisclosureSEC source: 0001104659-19-002494 · a4.xml · nonDerivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F1 · kind: On January 16, 2019, Mr. Van der Ploeg sold 200 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 17:20 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001104659-18-066381 · a4.xml · derivative · entry 7 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,894 Underlying: Common Stock · 10,000 shares Expires 2025-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 17:20 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001104659-18-066381 · a4.xml · derivative · entry 6 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,430 Underlying: Common Stock · 10,000 shares Expires 2027-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 17:20 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,200 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-18-066381 · a4.xml · derivative · entry 5 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,471 Underlying: Common Stock · 8,200 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 17:20 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 38,000 | $30.09 | $1,143,420.00 |
DisclosureSEC source: 0001104659-18-066381 · a4.xml · nonDerivative · entry 4 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,539 F1 · kind: On November 2, 2018, Mr. Van der Ploeg sold 38,000 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.31, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 17:20 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,000 | $7.52 | $75,200.00 |
DisclosureSEC source: 0001104659-18-066381 · a4.xml · nonDerivative · entry 3 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 17:20 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,000 | $6.14 | $61,400.00 |
DisclosureSEC source: 0001104659-18-066381 · a4.xml · nonDerivative · entry 2 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 17:20 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 8,200 | $4.59 | $37,638.00 |
DisclosureSEC source: 0001104659-18-066381 · a4.xml · nonDerivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,800 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-18-059105 · a4.xml · derivative · entry 8 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,671 Underlying: Common Stock · 21,800 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 6,102 | $31.86 | $194,409.72 |
DisclosureSEC source: 0001104659-18-059105 · a4.xml · nonDerivative · entry 7 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,339 F2 · kind: On September 25, 2018, Mr. Van der Ploeg sold 31,800 shares in multiple trades at prices ranging from $27.12 to $32.36 pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the "10b5-1 Plan"). F7 · price: This transaction was executed in multiple trades at prices ranging from $31.36 to $32.05, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,304 | $30.60 | $162,302.40 |
DisclosureSEC source: 0001104659-18-059105 · a4.xml · nonDerivative · entry 6 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,441 F2 · kind: On September 25, 2018, Mr. Van der Ploeg sold 31,800 shares in multiple trades at prices ranging from $27.12 to $32.36 pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the "10b5-1 Plan"). F6 · price: This transaction was executed in multiple trades at prices ranging from $30.21 to $31.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,656 | $29.81 | $228,225.36 |
DisclosureSEC source: 0001104659-18-059105 · a4.xml · nonDerivative · entry 5 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,745 F2 · kind: On September 25, 2018, Mr. Van der Ploeg sold 31,800 shares in multiple trades at prices ranging from $27.12 to $32.36 pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the "10b5-1 Plan"). F5 · price: This transaction was executed in multiple trades at prices ranging from $29.21 to $30.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 9,052 | $28.88 | $261,421.76 |
DisclosureSEC source: 0001104659-18-059105 · a4.xml · nonDerivative · entry 4 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,401 F2 · kind: On September 25, 2018, Mr. Van der Ploeg sold 31,800 shares in multiple trades at prices ranging from $27.12 to $32.36 pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the "10b5-1 Plan"). F4 · price: This transaction was executed in multiple trades at prices ranging from $28.20 to $29.19, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,686 | $27.45 | $101,180.70 |
DisclosureSEC source: 0001104659-18-059105 · a4.xml · nonDerivative · entry 3 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,453 F2 · kind: On September 25, 2018, Mr. Van der Ploeg sold 31,800 shares in multiple trades at prices ranging from $27.12 to $32.36 pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the "10b5-1 Plan"). F3 · price: This transaction was executed in multiple trades at prices ranging from $27.12 to $27.88, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff (the "Staff"), the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 21,800 | $4.59 | $100,062.00 |
DisclosureSEC source: 0001104659-18-059105 · a4.xml · nonDerivative · entry 2 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Sep 27, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-059105 · a4.xml · nonDerivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,339 F1 · kind: Mr. Van der Ploeg is voluntarily reporting a gift transfer of shares of common stock. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 16:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $25.79 | $0.00 |
DisclosureSEC source: 0001104659-18-010366 · a4.xml · derivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2028-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2018 and the shares underlying this option vest in sixteen equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.